Safety and Early Efficacy Analysis of a Novel Combination of the PARP Inhibitor Veliparib (ABT-888) Plus Bendamustine and Rituximab in Patients with Lymphoma

This article has no abstract
Epistemonikos ID: c648fb3bed9d14d40fcec8365938e9d6b5f968df
First added on: Feb 19, 2025